IN THIS ISSUE

Robert Calandra
The author’s nephew suffers from a rare form of familial hemophagocytic lymphohistiocytosis. His organs shut down and he’s placed in a medically induced coma. Meanwhile, costs mount to $4.9 million, most of it paid by an employer-sponsored health plan.
Ed Silverman
Prices of older drugs go up when new treatments are introduced. The difference between list and net price is also getting some fresh scrutiny.
Robert Calandra
They say their deals need to be kept private so they can drive a hard bargain with manufacturers. But employers, consumer groups, and legislators are calling for more PBM transparency.
Managing Editor’s Memo
Frank Diamond
Legislation & Regulation
Richard Mark Kirkner
The House has passed legislation that the AMA and others endorse. But the sense that there is a malpractice crisis has ebbed and Senate action is unlikely.
Medication Management
Thomas Reinke
Varying treatment strategies for a highly variable disease have given the new drug an opening—and, besides, it does OK when it comes to QALYs.
Tomorrow's Medicine
Thomas Morrow and Managed Care editors
FDA approval of the CAR T-cell therapy for leukemia could usher in an era of genetically engineered, individually tailored immunotherapies. But tap those brakes. Long-term results are in short supply—and there’s that $475,000 price tag.
News & Commentary